STA-9090 in Patients With Advanced Hepatocellular Cancer
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
STA-9090 works by inhibiting the function of a protein in tumor cells called Hsp90. Hsp90 is
thought to play a role in tumor growth. By interfering with this protein's function, STA-9090
may help kill tumor cells. This drug has been used in other research studies and information
from those studies suggests that this agent may help to slow tumor growth in HCC.
The purpose of this research study is to find the highest dose of STA-9090 that can safely be
given to participants with advanced HCC. The investigators will also get more information
about the safety of STA-9090 and perform tests to learn more about how STA-9090 affects the
body.
Phase:
Phase 1
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute Synta Pharmaceuticals Corp.